Dermata Therapeutics
DRMA
6 hedge funds and large institutions have $61.5K invested in Dermata Therapeutics in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.
482% more capital invested
Capital invested by funds: $10.6K → $61.5K (+$50.9K)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more funds holding
Funds holding: 4 → 6 (+2)
0.18% more ownership
Funds ownership: 0.04% → 0.22% (+0.18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$35.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$16K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$13 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.94K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $36.7K | +$35.1K | +2,720 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $18.7K | +$16K | +1,237 | +825% |
|
3
Wells Fargo
San Francisco,
California
| $2.76K | – | – | – |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $1.88K | -$1.94K | -150 | -52% |
|
|
SS
5
SBI Securities
Tokyo,
Japan
| $1.35K | +$1.29K | +100 | New |
|
|
6
Bank of America
Charlotte,
North Carolina
| $22 | +$13 | +1 | +100% |
|
DRMA Hedge Fund Activity: Q4 2024 in Review
6 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q4 2024, worth a combined $61.5K — up 482% from $10.6K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new DRMA positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $35.1K. The largest seller was Tower Research Capital (TRC), cutting an estimated $1.94K.
- 6 institutional investors held Dermata Therapeutics (DRMA) as of Q4 2024, up from 4 in Q3 2024.
- Funds reported $61.5K of Dermata Therapeutics stock for Q4 2024, up 482% quarter-over-quarter.
- 2 funds opened new Dermata Therapeutics positions in Q4 2024 and 0 closed out, a net change of +2 holders.
- The largest Dermata Therapeutics buyer in Q4 2024 was Armistice Capital, an estimated $35.1K added.
- The largest Dermata Therapeutics seller in Q4 2024 was Tower Research Capital (TRC), an estimated $1.94K sold.
Based on aggregated 13F filings for Q4 2024.